Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.

Seven murine monoclonal antibodies (MoAbs) recognizing differentiation antigens present on B-lymphocytes were analyzed in preclinical studies for their potential use for antibody-targeted therapy of B-cell malignancies. MoAbs HD37 (anti-CD19), 1F5 (anti-CD20), HD6 (anti-CD22), MB-1 (anti-CD37), G28-5 (anti-CDw40), 7.2 (anti-class II), and DA4-4 (anti-IgM) were studied for their binding avidities, immunoreactivities, isotypes, endocytosis rates, degradation rates, and number of binding sites on Daudi cells. Lineweaver-Burke analyses of 125I-labeled MoAbs demonstrated immunoreactivities ranging from 59 to 92%. Scatchard analyses of 125I-MoAbs demonstrated that five of the antibodies had binding avidities in excess of 10(9) L/M, whereas MoAbs 1F5 and HD37 had avidities of 3-4 x 10(8) L/M. CD20, CD37, mu, and HLA Class II were found to be highly expressed (200,000-400,000 binding sites/cell) on Daudi cells whereas CD19, CD22, and CDw40 were less densely expressed (80,000-100,000 sites/cell). DA4-4 (mu), HD6 (CD22), and G28-5 (CDw40) were rapidly internalized by cells, HD37 (CD19) and MB-1 (CD37) underwent endocytosis at an intermediate rate, and 7.2 (class II) and 1F5 (CD20) were internalized slowly. Trichloroacetic acid precipitation and high-performance liquid chromatography revealed the following relative rates of 125I-MoAb degradation: DA4-4 (mu) greater than HD6 (CD22) greater than HD37 (CD19) greater than G28-5 (CDw40) greater than MB-1 (CD37) greater than 1F5 (CD20) greater than 7.2 (class II).

Mouse strain differences in glutathione S-transferase activity and aflatoxin B1 biotransformation.

Previous studies have suggested that mice are resistant to the carcinogenic effects of aflatoxin B1 (AFB1) and that this resistance is largely the result of expression of an isoenzyme of glutathione S-transferase (GST) with high activity toward AFB1-8,9-epoxide. Significant interstrain differences in cytosolic GST activities toward a variety of substrates have been reported in mice. If such differences exist for the conjugation of AFB1-8,9-epoxide, then there may be significant mouse strain differences in susceptibility to AFB1-induced hepatocarcinogenicity. The hepatic microsomal and cytosolic biotransformation of AFB1 was studied in 8 different strains of mice fed a purified diet. GST-mediated conjugation of AFB1-8,9-epoxide with glutathione and GST activity toward 1-chloro-2,4-dinitrobenzene (CDNB), 1,2-dichloro-4-nitrobenzene (DCNB), ethacrynic acid (ECA) and cumene hydroperoxide (CHP) were determined with cytosolic fractions from 8-10 pooled livers. Specific activities of cytochrome-P-450-mediated oxidation of AFB1 to aflatoxin Q1 (AFQ1), aflatoxin M1 (AFM1), and aflatoxin P1 (AFP1), as well as the reactive intermediate AFB1-8,9-epoxide, were determined with hepatic microsomal fractions from each mouse strain. No striking differences in specific activity between mouse strains were observed for any of the P-450- or GST-mediated enzymatic pathways measured, although some statistically significant differences were found. GST specific activities toward AFB1-8,9-epoxide, CDNB, DCNB, ECA and CHP ranged from 1.5-2.1, 2,830-5,370, 81-144, 38-69 and 32-73 nmol/mg protein/min, respectively. The rate of formation of AFB1-8,9-epoxide ranged from 208 to 465 pmol/mg protein/min. The specific activities of AFQ1,AFM1, and AFP1 formation by microsomes ranged from 36-70, 161-326, and 252-426 pmol/mg protein/min, respectively. Mice fed a standard rodent chow diet showed evidence of microsomal and cytosolic enzyme induction when compared to mice fed a purified diet. The lack of substantial differences in enzyme specific activities between mouse strains suggests that interstrain variations in the hepatocarcinogenic effects of AFB1 in mice should not be large.

Modulation of gamma-glutamylcysteine synthetase large subunit mRNA expression by butylated hydroxyanisole.

Dietary 2(3)-tert-butyl-4-hydroxyanisole (BHA) treatment has been shown to increase hepatic glutathione (GSH) content in rats and mice. Subsequent studies in our laboratory have demonstrated that hepatic gamma-glutamylcysteine synthetase (GCS) activity is increased in mice treated with dietary BHA. To test whether this increase in GCS activity follows an increase in hepatic messenger RNA for the large subunit of GCS (GCS-LS mRNA), a 390-base pair fragment corresponding to a region near the 5' end of the rat GCS-LS cDNA sequence was amplified using the PCR reaction and used to detect GCS-LS mRNA on Northern blots. Hepatic GSH, GCS activity, and GCS-LS mRNA levels were determined either in mice treated with BHA in the diet for 12 days or mice injected with diethyl maleate (DEM), phorone, and/or DL-buthionine-[S,R]-sulfoximine (BSO) over a 24 hr period. BHA caused a 1.5-fold increase in GSH levels, a 1.7-fold increase in hepatic GCS activity by Day 12, and a rapid 5-fold increase in hepatic GCS mRNA levels reaching maximal levels after 2-3 days. Partial depletion of GSH with either phorone (70%) or DEM (50%) resulted in a 4- to 5-fold increase in hepatic GCS-LS mRNA levels by 9 hr and a 1.5- to 2-fold increase in hepatic GSH and GCS activity by 24 hr. Depletion of GSH with the GCS enzyme inhibitor BSO had no effect on GCS mRNA expression, even though GSH was depleted to 30%. When BSO was combined with the phorone treatment GSH levels were depleted to < 10%, but the large increase in GCS-LS mRNA seen with phorone alone was greatly attenuated. These data suggest that depletion of GSH per se, is not sufficient to induce elevation of GCS-LS mRNA levels, but that the formation of GSH conjugates may be required to trigger GCS-LS mRNA induction. The increase in GCS-LS mRNA levels may account for the increase in GCS activity and elevation of GSH observed following BHA treatment, as well as the "rebound" of GSH above control levels observed 18-24 hr following depletion of GSH by other chemicals. These results are consistent with the Michael acceptor, hypothesis by Talalay.

Differential effect of cyanohydroxybutene on glutathione synthesis in liver and pancreas of male rats.

1-Cyano-2-hydroxy-3-butene (CHB), an aliphatic nitrile found in cruciferous vegetables, causes a two- and sevenfold elevation in reduced glutathione (GSH) in rat liver and pancreas, respectively, after oral administration of 200 mg/kg. While this dose is also associated with pancreatotoxicity, a single 100 mg/kg dose or multiple lesser doses show the same effect, although somewhat reduced in magnitude, with no concomitant toxicity. In an attempt to identify the mechanism of this increase, we investigated the effect of CHB on GSH synthesis by examining the effect of buthionine sulfoximine (BSO), an inhibitor of GSH synthesis, on CHB-induced GSH elevation. Male Fischer 344 rats received 3 mmol BSO/kg ip 24 and 34 hr following CHB or corn oil. The CHB-mediated elevation in hepatic and pancreatic GSH was eradicated by BSO, suggesting that increased synthesis was responsible. The rate-limiting step in synthesis is gamma-glutamyl cysteine synthetase (GCS); the limiting substrate is cysteine. Therefore, CHB effects on GCS activity and hepatic and pancreatic cysteine equivalents were investigated. When rats were treated by gavage with CHB (100 mg/kg), hepatic GCS mRNA concentrations were increased 24 hr after treatment and hepatic cysteine equivalents were significantly elevated 4 hr following CHB. No significant elevation in hepatic GCS activity was observed, however, even 24 hr following CHB. Pancreatic cysteine equivalents were elevated at both 4 and 8 hr after CHB treatment. However, there was no detectable GCS mRNA or activity in pancreas, in either control or treated animals. Furthermore, CHB had no direct effect on the activity of GCS purified from kidney, regardless of whether GSH was present or absent. These results suggest that the mechanism of CHB-mediated induction of GSH may involve early increases in GSH precursors as well as a later increase in GCS mRNA. The mechanism of GSH elevation identified in these studies may hold therapeutic or prophylactic implications.